MIRA completes Ketamir-2 Phase 1, acquires SKNY adding obesity/nicotine asset, but losses rise 33%

Filed March 31, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 28, 2025 · ~2 min read

Key Changes

• high

  Ketamir-2 Phase 1 trial completed dosing in 56 participants with no serious adverse events or dissociative effects; Phase 2a in chemotherapy-induced neuropathy planned for H1 2026.

  Business: Ketamir-2 Phase 1 completion view on EDGAR →
• high

  Acquired SKNY Pharmaceuticals for 19.8M shares, adding SKNY-1 (preclinical obesity/nicotine candidate) but triggering $21.6M deemed dividend that pushed net loss to common holders to $32M.

  Notes: SKNY acquisition & deemed dividend verify on EDGAR →
• high

  Net loss increased 33% to $10.4M despite R&D spending falling 48%; G&A expenses nearly doubled to $8.8M driven by $6.3M in stock-based compensation (up from $1.9M).

  MD&A: Net loss & G&A expenses verify on EDGAR →